Journal Watch · Journal of Medicinal Chemistry · 2026

Discovery of Fragment-Based Inhibitors of SARS-CoV-2 PL<sup>Pro</sup>.

This novel class of PL<sup>Pro</sup> inhibitors can potentially be used as a starting point for the development of inhibitors to combat the emergence of drug-resistant viral strains and future coronavirus outbreaks.

Wei Q, Taylor AJ, Barmade MA et al.Journal of Medicinal Chemistry3 min readPharma relevance 60/100

DOI: 10.1021/acs.jmedchem.5c02832PMID: 41521555Study type: research study

TL;DR

This novel class of PL<sup>Pro</sup> inhibitors can potentially be used as a starting point for the development of inhibitors to combat the emergence of drug-resistant viral strains and future coronavirus outbreaks.

Key findings

  • This novel class of PL<sup>Pro</sup> inhibitors can potentially be used as a starting point for the development of inhibitors to combat the emergence of drug-resistant viral strains and future coronavirus outbreaks.

What they did

Here, we describe the discovery of potent PL<sup>Pro</sup> inhibitors by optimizing one of these hits via extensive medicinal chemistry guided by multiple X-ray structures of cocomplexes. Lead compound <b>46</b> is shown to bind to the S3 and S4 pockets with nanomolar affinity (0.4 μM) and exhibits robust cellular activity and resistance to mutation.

Full abstract (original)

Background: SARS-CoV-2 papain-like protease (PL<sup>Pro</sup>) plays a key role in viral replication and the host immune response and is a promising target for developing new antiviral treatments. We previously reported a fragment-based screen to identify hits that bind to SARS-CoV-2 PL<sup>Pro</sup>.

What they did: Here, we describe the discovery of potent PL<sup>Pro</sup> inhibitors by optimizing one of these hits via extensive medicinal chemistry guided by multiple X-ray structures of cocomplexes. Lead compound <b>46</b> is shown to bind to the S3 and S4 pockets with nanomolar affinity (0.4 μM) and exhibits robust cellular activity and resistance to mutation.

Results & conclusions: This novel class of PL<sup>Pro</sup> inhibitors can potentially be used as a starting point for the development of inhibitors to combat the emergence of drug-resistant viral strains and future coronavirus outbreaks.

Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.5c02832 · PubMed 41521555.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Medicinal Chemistry study find?

This novel class of PL<sup>Pro</sup> inhibitors can potentially be used as a starting point for the development of inhibitors to combat the emergence of drug-resistant viral strains and future coronavirus outbreaks.

What type of study is this?

It is a research study, published in Journal of Medicinal Chemistry in 2026. Here, we describe the discovery of potent PL<sup>Pro</sup> inhibitors by optimizing one of these hits via extensive medicinal chemistry guided by multiple X-ray structures of cocomplexes.

Where can I read the original paper?

The original is at the publisher via DOI 10.1021/acs.jmedchem.5c02832. PubMed ID: 41521555. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Wei Q, Taylor AJ, Barmade MA et al.. Discovery of Fragment-Based Inhibitors of SARS-CoV-2 PL&lt;sup&gt;Pro&lt;/sup&gt;.. Journal of Medicinal Chemistry (2026). DOI: 10.1021/acs.jmedchem.5c02832.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/discovery-of-fragment-based-inhibitors-of-sars-cov-2-pl-lt-sup-gt-pro-lt-c02832/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides